On May 28, 2019 Medtronic plc (NYSE:MDT), the global leader in medical technology, reported it will participate in the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5, 2019, in New York City (Press release, Medtronic, MAY 28, 2019, View Source;p=RssLanding&cat=news&id=2399814 [SID1234536602]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mike Coyle, executive vice president and president of Medtronic’s Cardiac and Vascular group (CVG), will answer questions about the company beginning at 11:00 a.m. EDT (10:00 a.m. CDT).

A live audio webcast of the session will be available on June 5, 2019, by clicking on the Investors Events link at View Source An archived audio file will be available for replay on the same webpage later in the day.

On May 28, 2019 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, reported that the Company’s management team will participate in the following upcoming investor conferences (Press release, Karyopharm, MAY 28, 2019, View Source [SID1234536601]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Jefferies 2019 Global Healthcare Conference on Wednesday, June 5, 2019, and will present at 3:00 p.m. ET.

The JMP Securities 2019 Life Sciences Conference on Wednesday, June 19, 2019, and will present at 11:30 a.m. ET.
A live webcast of the presentations can be accessed on the "Events & Presentations" page in the Investors section of the Company’s website, View Source A replay of each webcast will be archived on the Company’s website for 90 days following the presentation.

On May 28, 2019 Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, reported the Company and its subsidiaries will participate in the 2019 BIO International Convention June 3-6th in Philadelphia (Press release, Intrexon, MAY 28, 2019, View Source [SID1234536600]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pieter Rottiers, PhD, Chief Executive Officer of ActoBio Therapeutics, a wholly-owned subsidiary of Intrexon and innovative clinical-stage biotechnology company developing a new class of microbe-based therapeutic agents, will be giving a company presentation on Monday June 3rd from 2:15-2:30 pm ET.
Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon, will present in the session "It Starts with One Health: A Guide to Translational Science from Research to Investment" on Monday June 3rd from 2:30-4:00 pm ET, highlighting program areas in both Intrexon Health and Intrexon Bioengineering.
Helen Sabzevari, PhD, President of Precigen, Inc., a wholly-owned subsidiary of Intrexon and a clinical stage biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, will participate in the panel "Immuno-Oncology: Taking Immunotherapies to the Next Level" on June 6th from 10:30 am-12:00 pm ET.
The BIO International Convention in Philadelphia celebrates the globally important innovations in biotech that start with one: one meeting, one theory, one trial, one breakthrough. Attendees will take advantage of unparalleled business partnering, gain insights in hundreds of education sessions, and network with 16,000+ of biotech’s most influential. Learn more at convention.bio.org.

The companies’ presentations will not be webcast.

On May 28, 2019 Integral Molecular, the industry leader in discovering antibodies against multipass membrane proteins, reported that it has successfully reached the first milestone in its collaboration with Daiichi Sankyo Co., Ltd. to discover new immuno-oncology (I-O) therapeutic targets (Press release, Integral Molecular, MAY 28, 2019, https://www.integralmolecular.com/integral-molecular-reaches-milestone-in-immuno-oncology-target-discovery-collaboration-with-daiichi-sankyo/ [SID1234536599]). Integral Molecular utilized its Membrane Proteome Array (MPA) platform to find novel protein targets that can regulate the human immune system’s ability to recognize and destroy cancer cells. Daiichi Sankyo will use the newly identified targets to develop new therapeutics.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have enjoyed working with Daiichi Sankyo and we are very pleased to reach our first milestone," said Ben Doranz, President and CEO of Integral Molecular. "The success of our collaboration highlights the powerful target discovery capabilities of our MPA platform."

Integral Molecular has previously identified multiple novel therapeutic targets using its MPA platform. The platform is centered around an array of 5,300 human membrane proteins expressed in live, unfixed cells for binding and functional assays. Integral Molecular currently has target discovery programs in I-O, infectious disease, and neurodegeneration.

On May 28, 2019 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody therapeutic technology platform, reported that Sean McCarthy, D.Phil., president, chief executive officer and chairman, will deliver a corporate overview at the following healthcare conferences in June (Press release, CytomX Therapeutics, MAY 28, 2019, View Source [SID1234536598]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies 2019 Global Healthcare Conference

Date: Tuesday, June 4, 2019
Time: 10:30 a.m. ET
Location: New York, New York

Goldman Sachs 40th Annual Global Healthcare Conference

Date: Wednesday, June 12, 2019
Time: 2:40 p.m. PT
Location: Rancho Palos Verdes, California
Live audio webcast of these presentations will be available through the "Investors & News" section of CytomX’s website. An archived replay will be available for 90 days following the event.